Jazz Pharmaceuticals JAZZ Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's change in other liabilities?
- Jazz Pharmaceuticals (JAZZ) reported change in other liabilities of $12.2M in Q1 2026.
- How has Jazz Pharmaceuticals's change in other liabilities changed year-over-year?
- Jazz Pharmaceuticals's change in other liabilities increased by 320.7% year-over-year, from $2.9M to $12.2M.
- What is the long-term trend for Jazz Pharmaceuticals's change in other liabilities?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's change in other liabilities has grown at a 54.3% compound annual growth rate (CAGR), from -$4.95M to $28.02M.
- What does change in other liabilities mean?
- The change in miscellaneous short-term liabilities.
- How do you interpret change in other liabilities?
- An increase in other liabilities is a source of cash, while a decrease is a use of cash.
- How does change in other liabilities compare across companies?
- Varies by company; often reflects specific accounting treatments for deferred income or unique obligations.